Tobi (Tobramycin)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Tobi (Tobramycin)

TOBI®
(tobramycin) Inhalation Solution, USP

Nebulizer Solution – For Inhalation Use Only

DRUG DESCRIPTION

TOBI® is a tobramycin solution for inhalation. It is a sterile, clear, slightly yellow, non-pyrogenic, aqueous solution with the pH and salinity adjusted specifically for administration by a compressed air driven reusable nebulizer. The chemical formula for tobramycin is C18H37N5O9 and the molecular weight is 467.52. Tobramycin is O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1→6)]-2-deoxy-L-streptamine. The structural formula for tobramycin is:

TOBI (Tobramycin) Structural Formula Illustration

Each single-use 5 mL ampule contains 300 mg tobramycin and 11.25 mg sodium chloride in sterile water for injection. Sulfuric acid and sodium hydroxide are added to adjust the pH to 6.0. Nitrogen is used for sparging. All ingredients meet USP requirements. The formulation contains no preservatives.

What are the possible side effects of tobramycin (Tobi)?

If you experience any of the following serious side effects, stop using tobramycin and seek emergency medical attention or notify your doctor immediately:

  • an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
  • ringing in the ears or changes in hearing;
  • dizziness;
  • new or worsening respiratory problems or difficulty breathing;
  • muscle weakness; or
  • a rash.

If you experience any of the following less serious side effects, continue using tobramycin and talk to your...

Read All Potential Side Effects and See Pictures of Tobi »

What are the precautions when taking tobramycin (Tobi)?

Before using tobramycin inhalation solution, tell your doctor or pharmacist if you are allergic to it; or to other aminoglycoside antibiotics (such as gentamicin); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: hearing problems (including deafness, decreased hearing), kidney problems, myasthenia gravis, Parkinson's disease.

Tobramycin may cause live bacterial vaccines (such as typhoid vaccine) not to work as well. Therefore, do not have any immunizations/vaccinations while using this medication without the consent of your doctor.

Before...

Read All Potential Precautions of Tobi »

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

TOBI® (tobramycin) is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV1 < 25% or > 75% predicted, or patients colonized with Burkholderia cepacia (see Clinical Studies).

DOSAGE AND ADMINISTRATION

The recommended dosage for both adults and pediatric patients 6 years of age and older is 1 single-use ampule (300 mg) administered BID for 28 days. Dosage is not adjusted by weight. All patients should be administered 300 mg BID. The doses should be taken as close to 12 hours apart as possible; they should not be taken less than 6 hours apart.

TOBI® (tobramycin) is inhaled while the patient is sitting or standing upright and breathing normally through the mouthpiece of the nebulizer. Nose clips may help the patient breathe through the mouth.

TOBI® (tobramycin) is administered BID in alternating periods of 28 days. After 28 days of therapy, patients should stop TOBI® (tobramycin) therapy for the next 28 days, and then resume therapy for the next 28 day on/28 day off cycle.

TOBI® (tobramycin) is supplied as a single-use ampule and is administered by inhalation, using a hand-held PARI LC PLUS™ Reusable Nebulizer with a DeVilbiss® Pulmo-Aide® compressor. TOBI® (tobramycin) is not for subcutaneous, intravenous or intrathecal administration.

Usage

TOBI® (tobramycin) is administered by inhalation over an approximately 15-minute period, using a hand-held PARI LC PLUS™ Reusable Nebulizer with a DeVilbiss® Pulmo-Aide® compressor. TOBI® (tobramycin) should not be diluted or mixed with dornase alfa (PULMOZYME®, Genentech) in the nebulizer.

During clinical studies, patients on multiple therapies were instructed to take them first, followed by TOBI® (tobramycin) .

HOW SUPPLIED

TOBI® (tobramycin) 300 mg is available as follows:

NDC 0078-0494-71
5 mL single-dose ampule (carton of 56)

Storage

TOBI® (tobramycin) should be stored under refrigeration at 2-8?C/36-46?F. Upon removal from the refrigerator, or if refrigeration is unavailable, TOBI® (tobramycin) pouches (opened or unopened) may be stored at room temperature (up to 25?C/77?F) for up to 28 days. TOBI® (tobramycin) should not be used beyond the expiration date stamped on the ampule when stored under refrigeration (2-8?C/36-46?F) or beyond 28 days when stored at room temperature (25?C/77?F).

TOBI® (tobramycin) ampules should not be exposed to intense light. The solution in the ampule is slightly yellow, but may darken with age if not stored in the refrigerator; however, the color change does not indicate any change in the quality of the product as long as it is stored within the recommended storage conditions.

Manufactured by: Cardinal Health Woodstock, Illinois 60098. Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. REV: DECEMBER 2007. FDA Rev date: 10/16/2008

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

TOBI® (tobramycin) was generally well tolerated during two clinical studies in 258 cystic fibrosis patients ranging in age from 6 to 48 years. Patients received TOBI® (tobramycin) in alternating periods of 28 days on and 28 days off drug in addition to their standard cystic fibrosis therapy for a total of 24 weeks.

Voice alteration and tinnitus were the only adverse experiences reported by significantly more TOBI® (tobramycin) -treated patients. Thirty-three patients (13%) treated with TOBI® (tobramycin) complained of voice alteration compared to 17 (7%) placebo patients. Voice alteration was more common in the on-drug periods.

Eight patients from the TOBI® (tobramycin) group (3%) reported tinnitus compared to no placebo patients. All episodes were transient, resolved without discontinuation of the TOBI® (tobramycin) treatment regimen, and were not associated with loss of hearing in audiograms. Tinnitus is one of the sentinel symptoms of cochlear toxicity, and patients with this symptom should be carefully monitored for high frequency hearing loss. The numbers of patients reporting vestibular adverse experiences such as dizziness were similar in the TOBI® (tobramycin) and placebo groups.

Nine (3%) patients in the TOBI® (tobramycin) group and nine (3%) patients in the placebo group had increases in serum creatinine of at least 50% over baseline. In all nine patients in the TOBI® (tobramycin) group, creatinine decreased at the next visit.

Table 1 lists the percent of patients with treatment-emergent adverse experiences (spontaneously reported and solicited) that occurred in > 5% of TOBI® (tobramycin) patients during the two Phase III studies.

Table 1: Percent of Patients With Treatment Emergent Adverse Experiences Occurring in > 5% of TOBI® (tobramycin) Patients

Adverse Event TOBI® (tobramycin)
(n=258)
%
Placebo
(n=262)
%
Cough Increased 46.1 47.3
Pharyngitis 38.0 39.3
Sputum Increased 37.6 39.7
Asthenia 35.7 39.3
Rhinitis 34.5 33.6
Dyspnea 33.7 38.5
Fever1 32.9 43.5
Lung Disorder 31.4 31.3
Headache 26.7 32.1
Chest Pain 26.0 29.8
Sputum Discoloration 21.3 19.8
Hemoptysis 19.4 23.7
Anorexia 18.6 27.9
Lung Function Decreased2 16.3 15.3
Asthma 15.9 20.2
Vomiting 14.0 22.1
Abdominal Pain 12.8 23.7
Voice Alteration 12.8 6.5
Nausea 11.2 16.0
Weight Loss 10.1 15.3
Pain 8.1 12.6
Sinusitis 8.1 9.2
Ear Pain 7.4 8.8
Back Pain 7.0 8.0
Epistaxis 7.0 6.5
Taste Perversion 6.6 6.9
Diarrhea 6.2 10.3
Malaise 6.2 5.3
Lower Respiratory Tract Infection 5.8 8.0
Dizziness 5.8 7.6
Hyperventilation 5.4 9.9
Rash 5.4 6.1
1 Includes subjective complaints of fever.
2 Includes reported decreases in pulmonary function tests or decreased lung volume on chest radiograph associated with intercurrent illness or study drug administration.

Read the Tobi (tobramycin) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

In clinical studies of TOBI® (tobramycin) , patients taking TOBI® (tobramycin) concomitantly with dornase alfa (PULMOZYME®, Genentech), ß-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.

Concurrent and/or sequential use of TOBI® (tobramycin) with other drugs with neurotoxic or ototoxic potential should be avoided. Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. TOBI® (tobramycin) should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

Caution should be exercised when prescribing TOBI® (tobramycin) to patients with known or suspected renal, auditory, vestibular, or neuromuscular dysfunction. Patients receiving concomitant parenteral aminoglycoside therapy should be monitored as clinically appropriate.

Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides cross the placenta, and streptomycin has been associated with several reports of total, irreversible, bilateral congenital deafness in pediatric patients exposed in utero. Patients who use TOBI® (tobramycin) during pregnancy, or become pregnant while taking TOBI® (tobramycin) should be apprised of the potential hazard to the fetus.

Ototoxicity

Ototoxicity, as measured by complaints of hearing loss or by audiometric evaluations, did not occur with TOBI® (tobramycin) therapy during clinical studies. However, transient tinnitus occurred in eight TOBI® (tobramycin) -treated patients versus no placebo patients in the clinical studies. Tinnitus may be a sentinel symptom of ototoxicity, and therefore the onset of this symptom warrants caution (see ADVERSE REACTIONS). Ototoxicity, manifested as both auditory and vestibular toxicity, has been reported with parenteral aminoglycosides. Vestibular toxicity may be manifested by vertigo, ataxia or dizziness.

In postmarketing experience, patients receiving TOBI® (tobramycin) have reported hearing loss. Some of these reports occurred in patients with previous or concomitant treatment with systemic aminoglycosides. Patients with hearing loss frequently reported tinnitus.

Nephrotoxicity

Nephrotoxicity was not seen during TOBI® (tobramycin) clinical studies but has been associated with aminoglycosides as a class. If nephrotoxicity occurs in a patient receiving TOBI®, tobramycin therapy should be discontinued until serum concentrations fall below 2 µg/mL.

Muscular Disorders

TOBI® (tobramycin) should be used cautiously in patients with muscular disorders, such as myasthenia gravis or Parkinson's disease, since aminoglycosides may aggravate muscle weakness because of a potential curare-like effect on neuromuscular function.

Bronchospasm

Bronchospasm can occur with inhalation of TOBI® (tobramycin) . In clinical studies of TOBI® (tobramycin) , changes in FEV1 measured after the inhaled dose were similar in the TOBI® (tobramycin) and placebo groups. Bronchospasm should be treated as medically appropriate.

PRECAUTIONS

Included as part of the PATIENT INFORMATION section.

Laboratory Tests

Audiograms

Clinical studies of TOBI® (tobramycin) did not identify hearing loss using audiometric tests which evaluated hearing up to 8000 Hz. Physicians should consider an audiogram for patients who show any evidence of auditory dysfunction, or who are at increased risk for auditory dysfunction. Tinnitus may be a sentinel symptom of ototoxicity, and therefore the onset of this symptom warrants caution.

Serum Concentrations

In patients with normal renal function treated with TOBI®, serum tobramycin concentrations are approximately 1 µg/mL 1 hour after dose administration and do not require routine monitoring. Serum concentrations of tobramycin in patients with renal dysfunction or patients treated with concomitant parenteral tobramycin should be monitored at the discretion of the treating physician.

Renal Function

The clinical studies of TOBI® (tobramycin) did not reveal any imbalance in the percentage of patients in the TOBI® (tobramycin) and placebo groups who experienced at least a 50% rise in serum creatinine from baseline (see ADVERSE REACTIONS). Laboratory tests of urine and renal function should be conducted at the discretion of the treating physician.

Carcinogenesis, Mutagenesis, Impairment of Fertility

A two-year rat inhalation toxicology study to assess carcinogenic potential of TOBI® (tobramycin) has been completed. Rats were exposed to TOBI® (tobramycin) for up to 1.5 hours per day for 95 weeks. The clinical formulation of the drug was used for this carcinogenicity study. Serum levels of tobramycin of up to 35 mcg/mL were measured in rats, in contrast to the average 1 mcg/mL levels observed in cystic fibrosis patients in clinical trials. There was no drug-related increase in the incidence of any variety of tumor.

Additionally, TOBI® (tobramycin) has been evaluated for genotoxicity in a battery of in-vitro and in-vivo tests. The Ames bacterial reversion test, conducted with 5 tester strains, failed to show a significant increase in revertants with or without metabolic activation in all strains. Tobramycin was negative in the mouse lymphoma forward mutation assay, did not induce chromosomal aberrations in Chinese hamster ovary cells, and was negative in the mouse micronucleus test.

Subcutaneous administration of up to 100 mg/kg of tobramycin did not affect mating behavior or cause impairment of fertility in male or female rats.

Pregnancy

Teratogenic Effects – Pregnancy Category D

(See WARNINGS.)

No reproduction toxicology studies have been conducted with TOBI®. However, subcutaneous administration of tobramycin at doses of 100 or 20 mg/kg/day during organogenesis was not teratogenic in rats or rabbits, respectively. Doses of tobramycin 40 mg/kg/day were severely maternally toxic to rabbits and precluded the evaluation of teratogenicity. Aminoglycosides can cause fetal harm (e.g., congenital deafness) when administered to a pregnant woman. Ototoxicity was not evaluated in offspring during nonclinical reproduction toxicity studies with tobramycin. If TOBI® (tobramycin) is used during pregnancy, or if the patient becomes pregnant while taking TOBI® (tobramycin) , the patient should be apprised of the potential hazard to the fetus.

Nursing Mothers

It is not known if TOBI® (tobramycin) will reach sufficient concentrations after administration by inhalation to be excreted in human breast milk. Because of the potential for ototoxicity and nephrotoxicity in infants, a decision should be made whether to terminate nursing or discontinue TOBI® (tobramycin) .

Pediatric Use

The safety and efficacy of TOBI® (tobramycin) have not been studied in pediatric patients under 6 years of age.

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

Signs and symptoms of acute toxicity from overdosage of IV tobramycin might include dizziness, tinnitus, vertigo, loss of high-tone hearing acuity, respiratory failure, and neuromuscular blockade. Administration by inhalation results in low systemic bioavailability of tobramycin. Tobramycin is not significantly absorbed following oral administration. Tobramycin serum concentrations may be helpful in monitoring overdosage.

In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment. In the case of any overdosage, the possibility of drug interactions with alterations in drug disposition should be considered.

CONTRAINDICATIONS

TOBI® (tobramycin) is contraindicated in patients with a known hypersensitivity to any aminoglycoside.

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

TOBI® (tobramycin) is specifically formulated for administration by inhalation. When inhaled, tobramycin is concentrated in the airways.

Pharmacokinetics

TOBI® contains tobramycin, a cationic polar molecule that does not readily cross epithelial membranes.(1) The bioavailability of TOBI® (tobramycin) may vary because of individual differences in nebulizer performance and airway pathology.(2) Following administration of TOBI®, tobramycin remains concentrated primarily in the airways.

Sputum Concentrations: Ten minutes after inhalation of the first 300-mg dose of TOBI®, the average concentration of tobramycin was 1237 µg/g (ranging from 35 to 7414 µg/g) in sputum. Tobramycin does not accumulate in sputum; after 20 weeks of therapy with the TOBI® regimen, the average concentration of tobramycin at ten minutes after inhalation was 1154 µg/g (ranging from 39 to 8085 µg/g) in sputum. High variability of tobramycin concentration in sputum was observed. Two hours after inhalation, sputum concentrations declined to approximately 14% of tobramycin levels at ten minutes after inhalation.

Serum Concentrations:The average serum concentration of tobramycin one hour after inhalation of a single 300-mg dose of TOBI® (tobramycin) by cystic fibrosis patients was 0.95 µg/mL. After 20 weeks of therapy on the TOBI® regimen, the average serum tobramycin concentration one hour after dosing was 1.05 µg/mL.

Elimination: The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration. Assuming tobramycin absorbed following inhalation behaves similarly to tobramycin following IV administration, systemically absorbed tobramycin is eliminated principally by glomerular filtration. Unabsorbed tobramycin, following TOBI® (tobramycin) administration, is probably eliminated primarily in expectorated sputum.

Microbiology

Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius.(1) It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death.(3)

Tobramycin has in-vitro activity against a wide range of gram-negative organisms including Pseudomonas aeruginosa. It is bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.

Susceptibility Testing

A single sputum sample from a cystic fibrosis patient may contain multiple morphotypes of Pseudomonas aeruginosa and each morphotype may have a different level of in-vitro susceptibility to tobramycin. Treatment for 6 months with TOBI® (tobramycin) in two clinical studies did not affect the susceptibility of the majority of P. aeruginosa isolates tested; however, increased minimum inhibitory concentrations (MICs) were noted in some patients. The clinical significance of this information has not been clearly established in the treatment of P. aeruginosa in cystic fibrosis patients. For additional information regarding the effects of TOBI® (tobramycin) on P. aeruginosa MIC values and bacterial sputum density, please refer to the Clinical Studies section.

The in-vitroantimicrobial susceptibility test methods used for parenteral tobramycin therapy can be used to monitor the susceptibility of P. aeruginosa isolated from cystic fibrosis patients. If decreased susceptibility is noted, the results should be reported to the clinician.

Susceptibility breakpoints established for parenteral administration of tobramycin do not apply to aerosolized administration of TOBI® (tobramycin) . The relationship between in-vitro susceptibility test results and clinical outcome with TOBI® (tobramycin) therapy is not clear.

Clinical Studies

Two identically designed, double-blind, randomized, placebo-controlled, parallel group, 24-week clinical studies (Study 1 and Study 2) at a total of 69 cystic fibrosis centers in the United States were conducted in cystic fibrosis patients with P. aeruginosa. Subjects who were less than 6 years of age, had a baseline creatinine of > 2 mg/dL, or had Burkholderia cepacia isolated from sputum were excluded. All subjects had baseline FEV1 % predicted between 25% and 75%. In these clinical studies, 258 patients received TOBI® (tobramycin) therapy on an outpatient basis (see Table 2) using a hand-held PARI LC PLUS™ Reusable Nebulizer with a DeVilbiss® Pulmo-Aide® compressor.

Table 2: Dosing Regimens in Clinical Studies

  Cycle 1 Cycle 2 Cycle 3
28 days 28 days 28 days 28 days 28 days 28 days
TOBI® regimen n=258 TOBI® 300 mg BID No drug TOBI® 300 mg BID No drug TOBI® 300 mg BID No drug
Placebo placebo No drug placebo No drug placebo No drug
regimen n=262 BID BID BID

All patients received either TOBI® (tobramycin) or placebo (saline with 1.25 mg quinine for flavoring) in addition to standard treatment recommended for cystic fibrosis patients, which included oral and parenteral anti-pseudomonal therapy, β2-agonists, cromolyn, inhaled steroids, and airway clearance techniques. In addition, approximately 77% of patients were concurrently treated with dornase alfa (PULMOZYME®, Genentech).

In each study, TOBI® (tobramycin) -treated patients experienced significant improvement in pulmonary function. Improvement was demonstrated in the TOBI® (tobramycin) group in Study 1 by an average increase in FEV1 % predicted of about 11% relative to baseline (Week 0) during 24 weeks compared to no average change in placebo patients. In Study 2, TOBI® (tobramycin) -treated patients had an average increase of about 7% compared to an average decrease of about 1% in placebo patients. Figure 1 shows the average relative change in FEV1% predicted over 24 weeks for both studies.

Figure 1: Relative Change From Baseline in FEV1% Predicted

Relative Change From Baseline in FEV1% Predicted - Illustration

In each study, TOBI® (tobramycin) therapy resulted in a significant reduction in the number of P. aeruginosa colony forming units (CFUs) in sputum during the on-drug periods. Sputum bacterial density returned to baseline during the off-drug periods. Reductions in sputum bacterial density were smaller in each successive cycle. (see Figure 2).

Figure 2: Absolute Change From Baseline in Log10 CFUs

Absolute Change From Baseline in Log10 CFUs - Illustration

Patients treated with TOBI® (tobramycin) were hospitalized for an average of 5.1 days compared to 8.1 days for placebo patients. Patients treated with TOBI® (tobramycin) required an average of 9.6 days of parenteral anti-pseudomonal antibiotic treatment compared to 14.1 days for placebo patients. During the 6 months of treatment, 40% of TOBI® (tobramycin) patients and 53% of placebo patients were treated with parenteral anti-pseudomonal antibiotics.

The relationship between in-vitro susceptibility test results and clinical outcome with TOBI® (tobramycin) therapy is not clear. However, 4 TOBI® (tobramycin) patients who began the clinical trial with P. aeruginosa isolates having MIC values ≥ 128 µg/mL did not experience an improvement in FEV1 or a decrease in sputum bacterial density.

Treatment with TOBI® (tobramycin) did not affect the susceptibility of the majority of P. aeruginosa isolates during the 6-month studies. However, some P. aeruginosa isolates did exhibit increased tobramycin MICs. The percentage of patients with P. aeruginosa isolates with tobramycin MICs ≥ 16 µg/mL was 13% at the beginning, and 23% at the end of 6 months of the TOBI® (tobramycin) regimen.

REFERENCES

1. Neu HC. Tobramycin: an overview. [Review]. J Infect Dis 1976; Suppl 134:S3-19.

2. Weber A, Smith A, Williams-Warren J et al. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol 1994; 17 (5):331-9.

3. Bryan LE. Aminoglycoside resistance. Bryan LE, Ed. Antimicrobial drug resistance. Orlando, FL:Academic Press, 1984: 241-77.

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

NOTE: In addition to information provided below, a Patient Medication Guide providing instructions for proper use of TOBI® (tobramycin) is contained inside the package.

Safety Information

TOBI® (tobramycin) is in a class of antibiotics that have caused hearing loss, dizziness, kidney damage, and harm to a fetus. Ringing in the ears and hoarseness were two symptoms that were seen in more patients taking TOBI® (tobramycin) than placebo in research studies. Patients with cystic fibrosis can have many symptoms. Some of these symptoms may be related to your medications. If you have new or worsening symptoms, you should tell your doctor.

Hearing: You should tell your doctor if you have ringing in the ears, dizziness, or any changes in hearing.

Kidney Damage: Inform your doctor if you have any history of kidney problems.

Pregnancy: If you want to become pregnant or are pregnant while on TOBI® (tobramycin) , you should talk with your doctor about the possibility of TOBI® (tobramycin) causing any harm.

Nursing Mothers: If you are nursing a baby, you should talk with your doctor before using TOBI® (tobramycin) .

TOBI® (tobramycin) Packaging

TOBI® (tobramycin) comes in a single dose, ready-to-use ampule containing 300 mg tobramycin. Each foil pouch contains 4 ampules, for 2 days of TOBI® (tobramycin) therapy.

Dosage

The 300 mg dose of TOBI® (tobramycin) is the same for patients regardless of age or weight. TOBI® (tobramycin) has not been studied in patients less than 6 years old. Doses should be inhaled as close to 12 hours apart as possible and not less than 6 hours apart.

You should not mix TOBI® (tobramycin) with dornase alfa (PULMOZYME®, Genentech) in the nebulizer.

If you are taking several medications the recommended order is as follows: bronchodilator first, followed by chest physiotherapy, then other inhaled medications and, finally, TOBI® (tobramycin) .

Treatment Schedule

You should take TOBI® (tobramycin) in repeated cycles of 28 days on drug followed by 28 days off drug. You should take TOBI® (tobramycin) twice a day during the 28-day period on drug.

How To Administer TOBI® (tobramycin)

THIS INFORMATION IS NOT INTENDED TO REPLACE CONSULTATION WITH YOUR PHYSICIAN AND CF CARE TEAM ABOUT PROPERLY TAKING MEDICATION OR USING INHALATION EQUIPMENT.

TOBI® (tobramycin) is specifically formulated for inhalation using a PARI LC PLUS™ Reusable Nebulizer and a DeVilbiss® Pulmo-Aide® air compressor. TOBI® (tobramycin) can be taken at home, school, or at work. The following are instructions on how to use the DeVilbiss® Pulmo-Aide® air compressor and PARI LC PLUS™ Reusable Nebulizer to administer TOBI® (tobramycin) .

You will need the following supplies:

  • TOBI® (tobramycin) plastic ampule (vial)
  • DeVilbiss® Pulmo-Aide® air compressor
  • PARI LC PLUS™ Reusable Nebulizer
  • Tubing to connect the nebulizer and compressor
  • Clean paper or cloth towels
  • Nose clips (optional)

It is important that your nebulizer and compressor function properly before starting your TOBI® (tobramycin) therapy.

Note: Please refer to the manufacturers' care and use instructions for important information.

Preparing Your TOBI® (tobramycin) for Inhalation

  1. Wash your hands thoroughly with soap and water.
  2. a. TOBI® (tobramycin) is packaged with 4 ampules per foil pouch.
    b. Separate one ampule by gently pulling apart at the bottom tabs. Store all remaining ampules in the refrigerator as directed.
  3. Lay out the contents of a PARI LC PLUS™ Reusable Nebulizer package on a clean, dry paper or cloth towel. You should have the following parts:
    • Nebulizer Top and Bottom (Nebulizer Cup) Assembly
    • Inspiratory Valve Cap
    • Mouthpiece with Valve
    • Tubing
  4. Remove the Nebulizer Top from the Nebulizer Cup by twisting the Nebulizer Top counter-clockwise, and then lifting. Place the Nebulizer Top on the clean paper or cloth towel. Stand the Nebulizer Cup upright on the towel.
  5. Connect one end of the tubing to the compressor air outlet. The tubing should fit snugly. Plug in your compressor to an electrical outlet.
  6. Open the TOBI® (tobramycin) ampule by holding the bottom tab with one hand and twisting off the top of the ampule with the other hand. Be careful not to squeeze the ampule until you are ready to empty its contents into the Nebulizer Cup.
  7. Squeeze all the contents of the ampule into the Nebulizer Cup.
  8. Replace the Nebulizer Top. Note: In order to insert the Nebulizer Top into the Nebulizer Cup, the semi-circle halfway down the stem of the Nebulizer Top should face the Nebulizer Outlet.
  9. Attach the Mouthpiece to the Nebulizer Outlet. Then firmly push the Inspiratory Valve Cap in place on the Nebulizer Top. Note: the Inspiratory Valve Cap will fit snugly.
  10. Connect the free end of the tubing to the Air Intake on the bottom of the nebulizer, making sure to keep the nebulizer upright. Press the tubing on the Air Intake firmly.

TOBI® (tobramycin) Treatment

  1. Turn on the compressor.
  2. Check for a steady mist from the Mouthpiece. If there is no mist, check all tubing connections and confirm that the compressor is working properly.
  3. Sit or stand in an upright position that will allow you to breathe normally.
  4. Place Mouthpiece between your teeth and on top of your tongue and breathe normally only through your mouth. Nose clips may help you breathe through your mouth and not through your nose. Do not block airflow with your tongue.
  5. Continue treatment until all your TOBI® (tobramycin) is gone, and there is no longer any mist being produced. You may hear a sputtering sound when the Nebulizer Cup is empty. The entire TOBI® (tobramycin) treatment should take approximately 15 minutes to complete. Note: if you are interrupted, need to cough or rest during your TOBI® (tobramycin) treatment, turn off the compressor to save your medication. Turn the compressor back on when you are ready to resume your therapy.
  6. Follow the nebulizer cleaning and disinfecting instructions after completing therapy.

Cleaning Your Nebulizer

To reduce the risk of infection, illness or injury from contamination, you must thoroughly clean all parts of the nebulizer as instructed after each treatment. Never use a nebulizer with a clogged nozzle. If the nozzle is clogged, no aerosol mist is produced, which will alter the effectiveness of the treatment. Replace the nebulizer if clogging occurs.

  1. Remove tubing from nebulizer and disassemble nebulizer parts.
  2. Wash all parts (except tubing) with warm water and liquid dish soap.
  3. Rinse thoroughly with warm water and shake out water.
  4. Air dry or hand dry nebulizer parts on a clean, lint-free cloth. Reassemble nebulizer when dry, and store.
  5. You can also wash all parts of the nebulizer in a dishwasher (except tubing). Place the nebulizer parts in a dishwasher basket, then place on the top rack of the dishwasher. Remove and dry the parts when the cycle is complete.

Disinfecting Your Nebulizer

Your nebulizer is for your use only - Do not share your nebulizer with other people. You must regularly disinfect the nebulizer. Failure to do so could lead to serious or fatal illness.

Clean the nebulizer as described above. Every other treatment day, disinfect the nebulizer parts (except tubing) by boiling them in water for a full 10 minutes. Dry parts on a clean, lint-free cloth.

Care and Use of Your Pulmo-Aide® Compressor

Follow the manufacturer's instructions for care and use of your compressor.

Filter Change
  1. DeVilbiss® Compressor filters should be changed every six months or sooner if filter turns completely gray in color.
Compressor Cleaning
  1. With power switch in the "Off" position, unplug power cord from wall outlet.
  2. Wipe outside of the compressor cabinet with a clean, damp cloth every few days to keep dust free.

Caution: Do not submerge in water; doing so will result in compressor damage.

Storage Instructions

You should store TOBI® (tobramycin) ampules in a refrigerator (2-8°C or 36-46°F). However, when you don't have a refrigerator available (e.g., transporting your TOBI® (tobramycin) ), you may store the foil pouches (opened or unopened) at room temperature (up to 25°C/77°F) for up to 28 days.

Avoid exposing TOBI® (tobramycin) ampules to intense light.

Unrefrigerated TOBI® (tobramycin) , which is normally slightly yellow, may darken with age; however, the color change does not indicate any change in the quality of the product.

You should not use TOBI® (tobramycin) if it is cloudy, if there are particles in the solution, or if it has been stored at room temperature for more than 28 days. You should not use TOBI® (tobramycin) beyond the expiration date stamped on the ampule.

Additional Information

Nebulizer: 1-800-327-8632

Compressor: 1-800-333-4000

TOBI® (tobramycin) : 1-888-NOW-NOVA (1-888-669-6682)

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

NOTE: In addition to information provided below, a Patient Medication Guide providing instructions for proper use of TOBI® (tobramycin) is contained inside the package.

Safety Information

TOBI® (tobramycin) is in a class of antibiotics that have caused hearing loss, dizziness, kidney damage, and harm to a fetus. Ringing in the ears and hoarseness were two symptoms that were seen in more patients taking TOBI® (tobramycin) than placebo in research studies. Patients with cystic fibrosis can have many symptoms. Some of these symptoms may be related to your medications. If you have new or worsening symptoms, you should tell your doctor.

Hearing: You should tell your doctor if you have ringing in the ears, dizziness, or any changes in hearing.

Kidney Damage: Inform your doctor if you have any history of kidney problems.

Pregnancy: If you want to become pregnant or are pregnant while on TOBI® (tobramycin) , you should talk with your doctor about the possibility of TOBI® (tobramycin) causing any harm.

Nursing Mothers: If you are nursing a baby, you should talk with your doctor before using TOBI® (tobramycin) .

TOBI® (tobramycin) Packaging

TOBI® (tobramycin) comes in a single dose, ready-to-use ampule containing 300 mg tobramycin. Each foil pouch contains 4 ampules, for 2 days of TOBI® (tobramycin) therapy.

Dosage

The 300 mg dose of TOBI® (tobramycin) is the same for patients regardless of age or weight. TOBI® (tobramycin) has not been studied in patients less than 6 years old. Doses should be inhaled as close to 12 hours apart as possible and not less than 6 hours apart.

You should not mix TOBI® (tobramycin) with dornase alfa (PULMOZYME®, Genentech) in the nebulizer.

If you are taking several medications the recommended order is as follows: bronchodilator first, followed by chest physiotherapy, then other inhaled medications and, finally, TOBI® (tobramycin) .

Treatment Schedule

You should take TOBI® (tobramycin) in repeated cycles of 28 days on drug followed by 28 days off drug. You should take TOBI® (tobramycin) twice a day during the 28-day period on drug.

How To Administer TOBI® (tobramycin)

THIS INFORMATION IS NOT INTENDED TO REPLACE CONSULTATION WITH YOUR PHYSICIAN AND CF CARE TEAM ABOUT PROPERLY TAKING MEDICATION OR USING INHALATION EQUIPMENT.

TOBI® (tobramycin) is specifically formulated for inhalation using a PARI LC PLUS™ Reusable Nebulizer and a DeVilbiss® Pulmo-Aide® air compressor. TOBI® (tobramycin) can be taken at home, school, or at work. The following are instructions on how to use the DeVilbiss® Pulmo-Aide® air compressor and PARI LC PLUS™ Reusable Nebulizer to administer TOBI® (tobramycin) .

You will need the following supplies:

  • TOBI® (tobramycin) plastic ampule (vial)
  • DeVilbiss® Pulmo-Aide® air compressor
  • PARI LC PLUS™ Reusable Nebulizer
  • Tubing to connect the nebulizer and compressor
  • Clean paper or cloth towels
  • Nose clips (optional)

It is important that your nebulizer and compressor function properly before starting your TOBI® (tobramycin) therapy.

Note: Please refer to the manufacturers' care and use instructions for important information.

Preparing Your TOBI® (tobramycin) for Inhalation

  1. Wash your hands thoroughly with soap and water.
  2. a. TOBI® (tobramycin) is packaged with 4 ampules per foil pouch.
    b. Separate one ampule by gently pulling apart at the bottom tabs. Store all remaining ampules in the refrigerator as directed.
  3. Lay out the contents of a PARI LC PLUS™ Reusable Nebulizer package on a clean, dry paper or cloth towel. You should have the following parts:
    • Nebulizer Top and Bottom (Nebulizer Cup) Assembly
    • Inspiratory Valve Cap
    • Mouthpiece with Valve
    • Tubing
  4. Remove the Nebulizer Top from the Nebulizer Cup by twisting the Nebulizer Top counter-clockwise, and then lifting. Place the Nebulizer Top on the clean paper or cloth towel. Stand the Nebulizer Cup upright on the towel.
  5. Connect one end of the tubing to the compressor air outlet. The tubing should fit snugly. Plug in your compressor to an electrical outlet.
  6. Open the TOBI® (tobramycin) ampule by holding the bottom tab with one hand and twisting off the top of the ampule with the other hand. Be careful not to squeeze the ampule until you are ready to empty its contents into the Nebulizer Cup.
  7. Squeeze all the contents of the ampule into the Nebulizer Cup.
  8. Replace the Nebulizer Top. Note: In order to insert the Nebulizer Top into the Nebulizer Cup, the semi-circle halfway down the stem of the Nebulizer Top should face the Nebulizer Outlet.
  9. Attach the Mouthpiece to the Nebulizer Outlet. Then firmly push the Inspiratory Valve Cap in place on the Nebulizer Top. Note: the Inspiratory Valve Cap will fit snugly.
  10. Connect the free end of the tubing to the Air Intake on the bottom of the nebulizer, making sure to keep the nebulizer upright. Press the tubing on the Air Intake firmly.

TOBI® (tobramycin) Treatment

  1. Turn on the compressor.
  2. Check for a steady mist from the Mouthpiece. If there is no mist, check all tubing connections and confirm that the compressor is working properly.
  3. Sit or stand in an upright position that will allow you to breathe normally.
  4. Place Mouthpiece between your teeth and on top of your tongue and breathe normally only through your mouth. Nose clips may help you breathe through your mouth and not through your nose. Do not block airflow with your tongue.
  5. Continue treatment until all your TOBI® (tobramycin) is gone, and there is no longer any mist being produced. You may hear a sputtering sound when the Nebulizer Cup is empty. The entire TOBI® (tobramycin) treatment should take approximately 15 minutes to complete. Note: if you are interrupted, need to cough or rest during your TOBI® (tobramycin) treatment, turn off the compressor to save your medication. Turn the compressor back on when you are ready to resume your therapy.
  6. Follow the nebulizer cleaning and disinfecting instructions after completing therapy.

Cleaning Your Nebulizer

To reduce the risk of infection, illness or injury from contamination, you must thoroughly clean all parts of the nebulizer as instructed after each treatment. Never use a nebulizer with a clogged nozzle. If the nozzle is clogged, no aerosol mist is produced, which will alter the effectiveness of the treatment. Replace the nebulizer if clogging occurs.

  1. Remove tubing from nebulizer and disassemble nebulizer parts.
  2. Wash all parts (except tubing) with warm water and liquid dish soap.
  3. Rinse thoroughly with warm water and shake out water.
  4. Air dry or hand dry nebulizer parts on a clean, lint-free cloth. Reassemble nebulizer when dry, and store.
  5. You can also wash all parts of the nebulizer in a dishwasher (except tubing). Place the nebulizer parts in a dishwasher basket, then place on the top rack of the dishwasher. Remove and dry the parts when the cycle is complete.

Disinfecting Your Nebulizer

Your nebulizer is for your use only - Do not share your nebulizer with other people. You must regularly disinfect the nebulizer. Failure to do so could lead to serious or fatal illness.

Clean the nebulizer as described above. Every other treatment day, disinfect the nebulizer parts (except tubing) by boiling them in water for a full 10 minutes. Dry parts on a clean, lint-free cloth.

Care and Use of Your Pulmo-Aide® Compressor

Follow the manufacturer's instructions for care and use of your compressor.

Filter Change
  1. DeVilbiss® Compressor filters should be changed every six months or sooner if filter turns completely gray in color.
Compressor Cleaning
  1. With power switch in the "Off" position, unplug power cord from wall outlet.
  2. Wipe outside of the compressor cabinet with a clean, damp cloth every few days to keep dust free.

Caution: Do not submerge in water; doing so will result in compressor damage.

Storage Instructions

You should store TOBI® (tobramycin) ampules in a refrigerator (2-8°C or 36-46°F). However, when you don't have a refrigerator available (e.g., transporting your TOBI® (tobramycin) ), you may store the foil pouches (opened or unopened) at room temperature (up to 25°C/77°F) for up to 28 days.

Avoid exposing TOBI® (tobramycin) ampules to intense light.

Unrefrigerated TOBI® (tobramycin) , which is normally slightly yellow, may darken with age; however, the color change does not indicate any change in the quality of the product.

You should not use TOBI® (tobramycin) if it is cloudy, if there are particles in the solution, or if it has been stored at room temperature for more than 28 days. You should not use TOBI® (tobramycin) beyond the expiration date stamped on the ampule.

Additional Information

Nebulizer: 1-800-327-8632

Compressor: 1-800-333-4000

TOBI® (tobramycin) : 1-888-NOW-NOVA (1-888-669-6682)

Last reviewed on RxList: 11/21/2008
This monograph has been modified to include the generic and brand name in many instances.

Disclaimer

Tobi Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

TOBRAMYCIN SOLUTION - INHALATION

(TOE-bra-MYE-sin)

COMMON BRAND NAME(S): Tobi

USES: This medication is used to treat people with a certain inherited condition (cystic fibrosis) who have a persistent lung infection with a certain bacteria (Pseudomonas aeruginosa). People with cystic fibrosis produce thick, sticky mucus that can plug up the tubes, ducts and passageways in the lungs. This can result in serious breathing problems and infections in the lungs.

Tobramycin belongs to a class of drugs known as aminoglycoside antibiotics. Tobramycin inhalation solution works by stopping the growth of a certain bacteria (Pseudomonas aeruginosa) that commonly infects the lungs of people with cystic fibrosis. This effect decreases lung infections and damage, and helps to improve breathing.

HOW TO USE: Read the Patient Information Leaflet provided by your pharmacist before you start using this medication and each time you get a refill. This medication is used with a special machine called a nebulizer that changes the solution to a fine mist that you inhale. Learn and follow all instructions for the use of this medication and the nebulizer. Children may need help from an adult to use this medication properly. If you have any questions, ask your doctor, pharmacist, or respiratory therapist.

Use this medication with the nebulizer every 12 hours or as directed by your doctor. Each treatment lasts about 15 minutes. This medicine is usually used for 28 days in a row, followed by 28 days without this medication, repeating the cycle until your doctor directs you to stop.

Each ampule of tobramycin is for one-time use. Inspect each ampule before use. Normal solution is slightly yellow and may darken with age. Discard the ampule if the solution is cloudy or has particles in it, or if it has expired or has been stored at room temperature for longer than 28 days. Use all of the contents of the ampule for each dose. Do not mix tobramycin with any other medicines in the nebulizer.

Antibiotics work best when the amount of medicine in your body is kept at a constant level. Therefore, take this drug at evenly spaced intervals.

Continue to take this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may result in a return of the infection.

Tell your doctor if your condition does not improve or if it worsens.

Disclaimer

Tobi Consumer (continued)

SIDE EFFECTS: Hoarseness and changes in voice may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: signs of hearing damage (such as ringing/roaring sounds in the ears, hearing loss, dizziness), unusual decrease in the amount of urine.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, wheezing/unusual trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the Tobi (tobramycin) Side Effects Center for a complete guide to possible side effects »

PRECAUTIONS: Before using tobramycin inhalation solution, tell your doctor or pharmacist if you are allergic to it; or to other aminoglycoside antibiotics (such as gentamicin); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: hearing problems (including deafness, decreased hearing), kidney problems, myasthenia gravis, Parkinson's disease.

Tobramycin may cause live bacterial vaccines (such as typhoid vaccine) not to work as well. Therefore, do not have any immunizations/vaccinations while using this medication without the consent of your doctor.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

This medication is not recommended for use during pregnancy. Although there have been reports of harm in babies born to women using similar drugs, the risk for harm may not be the same with this drug. Discuss the risks and benefits with your doctor.

It is unknown if inhaled tobramycin passes into breast milk. However, other forms of this drug pass into breast milk in very small amounts, and many doctors consider breastfeeding safe while using this drug. Consult your doctor before breastfeeding.

Disclaimer

Tobi Consumer (continued)

DRUG INTERACTIONS: The effects of some drugs can change if you take other drugs or herbal products at the same time. This can increase your risk for serious side effects or may cause your medications not to work correctly. These drug interactions are possible, but do not always occur. Your doctor or pharmacist can often prevent or manage interactions by changing how you use your medications or by close monitoring.

To help your doctor and pharmacist give you the best care, be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products) before starting treatment with this product. While using this product, do not start, stop, or change the dosage of any other medicines you are using without your doctor's approval.

Other medications that may affect hearing may increase the risk of hearing loss if taken with tobramycin. Some affected drugs include: amikacin, gentamicin, mannitol, "water pills"/diuretics such as furosemide, among others.

This document does not contain all possible drug interactions. Keep a list of all the products you use. Share this list with your doctor and pharmacist to lessen your risk for serious medication problems.

OVERDOSE: Overdose is unlikely with tobramycin that is inhaled or swallowed. However, if overdose is suspected, contact a local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Do not share this medication with others.

Laboratory and/or medical tests (such as breathing tests, hearing tests) may be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

MISSED DOSE: If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store ampules in the refrigerator between 36-46 degrees F (2-8 degrees C) away from light. Ampules may also be stored at room temperature up to 77 degrees F (25 degrees C) for up to 28 days. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired, or no longer needed, or if it has been stored at room temperature for more than 28 days. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-800-854-1166 (US) or 1-800-668-1507 (Canada).

Information last revised May 2011. Copyright(c) 2011 First Databank, Inc.

Tobi Patient Information Including Side Effects

Brand Names: Tobi

Generic Name: tobramycin (inhalation) (Pronunciation: toe bra MY sin)

What is tobramycin (Tobi)?

Tobramycin is an antibiotic. It fights bacteria in the body.

Tobramycin inhalation is inhaled into the lungs using a nebulizer. Tobramycin inhalation is used to treat lung infections in patients with cystic fibrosis.

Tobramycin may also be used for purposes other than those listed here.

What are the possible side effects of tobramycin (Tobi)?

If you experience any of the following serious side effects, stop using tobramycin and seek emergency medical attention or notify your doctor immediately:

  • an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
  • ringing in the ears or changes in hearing;
  • dizziness;
  • new or worsening respiratory problems or difficulty breathing;
  • muscle weakness; or
  • a rash.

If you experience any of the following less serious side effects, continue using tobramycin and talk to your doctor:

  • changes in voice; or
  • unpleasant taste or odor of the medication.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.

Read the Tobi (tobramycin) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about tobramycin (Tobi)?

Notify your doctor immediately if you develop ringing in the ears, dizziness, or changes in hearing during treatment with tobramycin.

To reduce the risk of illness, infection, or injury from contamination, you must thoroughly clean all parts of the nebulizer as directed after each treatment.

Side Effects Centers

Tobi Patient Information including How Should I Take

What should I discuss with my healthcare provider before using tobramycin (Tobi)?

Do not use tobramycin without first talking to your doctor if you have had an allergic reaction to an aminoglycoside antibiotic such as tobramycin (Nebcin, Tobi), gentamicin (Garamycin, others), amikacin (Amikin), kanamycin (Kantrex), streptomycin, paromomycin, or neomycin.

Talk to your doctor before using tobramycin if you have

  • hearing problems;
  • a neuromuscular disease such as myasthenia gravis or Parkinson's disease; or
  • kidney disease.

You may not be able to use tobramycin, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.

Tobramycin is in the FDA pregnancy category D. This means that it is known to be harmful to an unborn baby. Tobramycin is known to cause deafness in the baby when taken during pregnancy. Do not use tobramycin without first talking to your doctor if you are pregnant or could become pregnant during treatment.

It is not known whether tobramycin passes into breast milk. Do not use tobramycin without first talking to your doctor if you are breast-feeding a baby.

How should I use tobramycin (Tobi)?

Use tobramycin exactly as directed by your doctor. If you do not understand these instructions, ask your pharmacist, nurse, or doctor to explain them to you.

Tobramycin is inhaled into the lungs with the use of a nebulizer. Do not swallow the solution by mouth.

Wash your hands with soap and water before preparing each treatment.

To use tobramycin inhalation:

  • Set up the nebulizer as directed.
  • Open one ampule of tobramycin solution for inhalation and squeeze the contents of the ampule into the nebulizer cup. Replace the nebulizer top.
  • Turn on the compressor. Check for a steady mist from the mouthpiece. If there is no mist, check all tubing connections and make sure the compressor is working.
  • Sit or stand in a position that will allow you to breathe normally. Place the mouthpiece of the nebulizer between your teeth and above your tongue and breathe normally only through your mouth. A noseclip may help you to breathe only through your mouth during a treatment. Continue breathing through the mouthpiece until all of the medicine is gone and no more mist is being produced. You may hear a sputtering sound when the nebulizer cup is empty. The entire treatment should take approximately 15 minutes to complete.
  • If you are interrupted or need to cough or rest during a treatment, turn the compressor off to save the medication. Turn the compressor back on when you are ready to resume treatment.

To reduce the risk of illness, infection, or injury from contamination, you must thoroughly clean all parts of the nebulizer as directed after each treatment.

If you are using several respiratory medications, the recommended order is bronchodilator first, followed by chest physiotherapy, then other inhaled medications, followed by tobramycin.

Do not use tobramycin that is cloudy or that has particles in it. Tobramycin stored at room temperature may become a darker color of yellow. This does not indicate any change in quality of the medication.

Do not mix tobramycin with dornase alfa (Pulmozyme) or any other medications in the nebulizer.

Do not use tobramycin in bigger doses or more often than prescribed.

Use all of the tobramycin that has been prescribed for you even if you begin to feel better. Your symptoms may start to improve before the infection is completely treated.

Store tobramycin in the refrigerator between 36 and 46 degrees Fahrenheit (2 and 8 degrees Celsius). If refrigeration is not available (e.g., when traveling), tobramycin may be stored at room temperature (77 degrees Fahrenheit/25 degrees Celsius) for up to 28 days. Avoid exposing ampules of tobramycin to direct light. Do not use tobramycin beyond the expiration date printed on the ampule.

Side Effects Centers

Tobi Patient Information including If I Miss a Dose

What happens if I miss a dose (Tobi)?

Use the missed dose as soon as you remember. However, if it is less than six hours until the next scheduled dose, skip the missed dose and use only the next regularly scheduled dose. Do not use a double dose of this medication.

What happens if I overdose (Tobi)?

Seek emergency medical attention if an overdose is suspected.

Symptoms of a tobramycin overdose may include dizziness, ringing in the ears, loss of hearing, difficulty or decreased breathing, and weakness.

What should I avoid while using tobramycin (Tobi)?

Do not mix tobramycin with dornase alfa (Pulmozyme) in the nebulizer.

What other drugs will affect tobramycin (Tobi)?

Before using tobramycin, tell your doctor if you are taking:

  • furosemide (Lasix);
  • ethacryinc acid (Edecrin); or
  • mannitol (Osmitrol).

You may not be able to use tobramycin, or you may require a dosage adjustment or special monitoring during treatment if you are taking any of the medicines listed above.

Do not mix tobramycin with dornase alfa (Pulmozyme) in the nebulizer.

Drugs other than those listed here may also interact with tobramycin. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products.

Where can I get more information?

Your pharmacist has additional information about tobramycin written for health professionals that you may read.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 1.06. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com